In Vivo Metabolism and Binding of 6α-Methylprogesterone; A Progestin with Anti-Androgenic and Synandrogenic Activities

  • Terry R. Brown
  • Leslie P. Bullock
  • C. Wayne Bardin
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 117)

Summary

The synthetic progestin 6α-methylprogesterone (6MP) was shown to have androgenic, synandrogenic and anti-androgenic actions on mouse kidney. In vitro studies indicated that 6MP competes with testosterone for binding sites on the androgen receptor in kidney cytosol and nuclei. The in vivo distribution of 6MP and testosterone differed following subcutaneous administration: Testosterone levels were 10 and 100-fold higher than those of 6MP in plasma and nuclei from prostate-seminal vesicle. In kidney nuclei, the concentrations of these two steroids were similar. In addition, kidney nuclei bound a hydroxylated metabolite of 6MP as well as the parent compound, whereas only 6MP was found in nuclei from prostate-seminal vesicle. In vivo competition studies indicated that nonradioactive 6MP and testosterone decreased the uptake of 3H-testosterone by nuclei of kidney and prostate-seminal vesicle. By contrast, 3H-6MP uptake in kidney nuclei was potentiated by the prior administration of 6MP or testosterone. These results suggest that factors in addition to the androgen receptor may be involved in the binding and mechanism of action of 6MP on mouse kidney.

Keywords

Androgen Receptor Seminal Vesicle Mouse Kidney Nuclear Binding Relative Binding Affinity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Swank, R.T., Paigen, K. and Ganschow, R.E. (1973). J. Mol. Biol. 81: 225–243.Google Scholar
  2. 2.
    Mowszowicz, I., Bieber, D.E., Chung, K.W., Bullock, L.P. and Bardin, C.W. (1974). Endocrinology 95: 1589–1599.PubMedCrossRefGoogle Scholar
  3. 3.
    Gupta, C., Bullock, L.P. and Bardin, C.W. (1978). Endocrinology 102: 736–744.PubMedCrossRefGoogle Scholar
  4. 4.
    Bullock, L.P., Bardin, C.W. and Sherman, M.R. (1978). Endocrinology 103: 1768–1782.PubMedCrossRefGoogle Scholar
  5. 5.
    Fang, S., Anderson, K.M. and Liao, S. (1969). J. Biol. Chem. 244: 6584–6595.Google Scholar
  6. 6.
    Baulieu, E.-E. and Jung, I. (1970). Biochem. Biophys. Res. Commun. 38: 599–606.Google Scholar
  7. 7.
    Mangan, F.R. and Mainwaring, W.I.P. (1972). Steroids 20: 331–343.PubMedCrossRefGoogle Scholar
  8. 8.
    Bardin, C.W., Brown, T.R., Mills, N.C., Gupta, C. and Bullock, L.P. (1978). Biol. Reprod. 18: 74–83.PubMedCrossRefGoogle Scholar
  9. 9.
    Bullock, L.P., Lin, Y.C., Jacob, S.T. and Bardin, C.W. (1977). In: Pharmacology of Steroid Contraceptive Drugs, edited by S. Garattini and H.W. Berendes, pp. 353–363, Raven Press, New York.Google Scholar
  10. 10.
    Bullock, L.P. and Bardin, C.W. (1977). Ann. N.Y. Acad. Sci. 286: 321–330.Google Scholar
  11. 11.
    Brown, T.R., Bullock, L.P. and Bardin, C.W. (1979). Endocrinology, in press.Google Scholar
  12. 12.
    Bullock, L.P. and Bardin, C.W. (1975). Steroids 25: 107–119.PubMedCrossRefGoogle Scholar
  13. 13.
    Gupta, C., Osterman, J., Miljkovic, M. and Bardin, C.W. (1977). Steroids 29: 669–677.PubMedCrossRefGoogle Scholar
  14. 14.
    Burton, K. (1961). Biochemistry 62: 315–323.Google Scholar

Copyright information

© Springer Science+Business Media New York 1979

Authors and Affiliations

  • Terry R. Brown
    • 1
    • 2
  • Leslie P. Bullock
    • 1
    • 2
  • C. Wayne Bardin
    • 1
    • 2
  1. 1.Department of Medicine, The M.S. Hershey Medical CenterThe Pennsylvania State University College of MedicineHersheyUSA
  2. 2.the Population CouncilRockefeller UniversityNew YorkUSA

Personalised recommendations